Dermorphin

A heptapeptide from the skin of Phyllomedusa frogs carrying a D-alanine at position 2 and very high mu-opioid receptor selectivity, studied briefly in humans in the 1980s and known since 2012 chiefly as a racehorse doping agent.

Also referenced as: Dermorphine

What is Dermorphin?

Dermorphin is a linear heptapeptide with the sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, a C-terminal amide, and a molecular weight near 803 Da. It was isolated from skin extracts of the South American frog Phyllomedusa sauvagei by Montecucchi, Erspamer, and colleagues, who reported its composition and sequence in 1981 and noted the rarity of a D-amino acid residue in a vertebrate peptide (Montecucchi et al., International Journal of Peptide and Protein Research, 1981, 17(3):275–283). The same year the peptide and its hydroxyproline variant, Hyp6-dermorphin, were identified in skin extracts of the Brazilian species Phyllomedusa rhodei (Montecucchi et al., International Journal of Peptide and Protein Research, 1981, 17(3):316–321), and the D-alanine itself was later shown to be installed after translation: the cloned precursor carries an ordinary L-alanine codon at that position (Richter et al., Science, 1987, 238(4824):200–202).

Pharmacologically it is one of the most potent and most mu-selective opioid agonists known from nature, which is why it circulates at all. It has no approved drug product anywhere, no development program, and no registered clinical trial. It exists commercially as a laboratory reagent, and its public profile rests on two things: a cluster of small Italian human studies from the 1980s that were never followed up, and its emergence from 2012 onward as an illicit painkiller in horse racing, where it acquired the nickname “frog juice.”

How it works

• Highly selective mu-opioid receptor agonism, with potency well above morphine. In the original pharmacological characterization, dermorphin was 39 times more potent than morphine at depressing electrically stimulated contractions of the guinea-pig ileum and 40 times more potent on the mouse vas deferens; naloxone was a powerful antagonist in both preparations. After intracerebroventricular injection in rats the analgesic ED50 was on the order of 13–23 pmol per animal, and morphine was 752 to 2,170 times less potent depending on the test (Broccardo et al., British Journal of Pharmacology, 1981, 73(3):625–631). Binding work with dermorphin-related peptides from Phyllomedusa bicolor later suggested two mu-receptor subtypes of high and low affinity, with the high-affinity-preferring ligand producing antinociception and the low-affinity-preferring ligand producing weak antinociception but intense catalepsy (Negri et al., Proceedings of the National Academy of Sciences, 1992, 89(15):7203–7207).
• The N-terminal tetrapeptide is the active core and the D-alanine is essential. The minimum sequence for full activity is Tyr-D-Ala-Phe-Gly, and replacing D-Ala2 abolishes potency (Broccardo et al., 1981). The D-residue also blocks the aminopeptidase cleavage that destroys enkephalins within minutes, which is the basis of dermorphin’s long duration of action and of the analog literature built on tetrapeptides carrying D-Arg2 in place of D-Ala2 (Mizoguchi et al., Peptides, 2011, 32(2):421–427).
• Central and peripheral activity after systemic exposure. Dermorphin produced potent, long-lasting analgesia in mice when given intravenously, not only when injected into the brain (Broccardo et al., 1981), and the family review from the discovering group states that some dermorphins cross the blood-brain barrier and produce central antinociception after peripheral administration (Melchiorri & Negri, General Pharmacology, 1996, 27(7):1099–1107). Brain uptake of the stable analog DALDA, measured directly, was comparable to that of sucrose and consistent with slow nonsaturable diffusion (Samii et al., American Journal of Physiology, 1994, 267(1 Pt 1):E124–E131), enough for activity but not efficient brain penetration.
• Opioid-typical neuroendocrine effects in humans. Intravenous infusion in healthy volunteers raised plasma prolactin, growth hormone, thyrotropin, and renin activity and lowered cortisol; naloxone pretreatment suppressed the prolactin and thyrotropin responses and prevented the cortisol fall, placing the effects at mu-type opioid receptors (Degli Uberti et al., Peptides, 1985, 6 Suppl 3:171–175; Degli Uberti et al., Journal of Clinical Endocrinology and Metabolism, 1983, 56(5):1032–1034; Degli Uberti et al., Neuroendocrinology, 1983, 37(4):280–283).

Research status

Preclinical pharmacology is thorough and describes a conventional, if unusually potent, mu agonist. Beyond analgesia, the 1981 characterization recorded catalepsy at high intracerebroventricular doses, and chronic intracerebroventricular infusion produced tolerance and naloxone-precipitated withdrawal, both judged less marked than with morphine (Broccardo et al., 1981). A dedicated follow-up confirmed the picture: tolerance to analgesia, catalepsy, and rigidity developed dose-dependently within 48 hours of continuous intracerebroventricular infusion in rats, a dependent state was established after three days, and naloxone precipitated escape behavior, shaking, salivation, and rhinorrhea — qualitatively the same syndrome seen in morphine-dependent rats (Broccardo et al., European Journal of Pharmacology, 1985, 110(1):55–61). Respiratory effects have been documented too: an intravenous bolus in anesthetized, spontaneously breathing rats evoked apnea followed by slowed breathing with a compensatory rise in tidal volume, together with hypotension and a transient fall in heart rate, none of which appeared after bilateral supranodose vagotomy (Wojciechowski et al., European Journal of Pharmacology, 2007, 563(1-3):209–212).

Human exposure is confined to a small set of Italian studies from 1983 to 1986, none of which led anywhere. The endocrine infusion studies in healthy volunteers are summarized above. A neurophysiology study showed that intravenous dermorphin produced a marked, long-lasting rise in the threshold of the nociceptive flexion reflex, including in a subject with a complete chronic spinal lesion, which placed the effect mainly at the spinal level; notably, naloxone reversed only about half of the effect even though it fully antagonized morphine and an enkephalin analog in the same paradigm (Sandrini et al., Brain Research, 1986, 371(2):364–367). The only efficacy study on record compared intrathecal dermorphin, intrathecal morphine, and routine intramuscular pentazocine in 150 consecutive patients after elective surgery in a randomized, double-blind design: dermorphin analgesia was described as profound and the longest-lasting of the three, with no significant difference in side effects such as urinary retention, vomiting, or headache among the groups (Basso et al., Peptides, 1985, 6 Suppl 3:177–179). That result was published as a three-page conference supplement, was never replicated, and was never carried into a registered trial; a 2019 commentary in Pain Medicine revisited it as a missed opportunity for intrathecal therapy in oncological patients, which is itself a measure of how little followed (Liebregts et al., Pain Medicine, 2019, 20(10):2077–2079).

No registered trials, no application, no label. A ClinicalTrials.gov search for dermorphin returns no studies, an openFDA drug-label query returns no match, and no regulatory authority has approved a dermorphin product.

The analog lineage is where the chemistry went, and it left opioids behind. Adding positive charge to the dermorphin tetrapeptide produced DALDA, [D-Arg2, Lys4]dermorphin-(1-4)-amide, with a Ki(delta)/Ki(mu) selectivity ratio of 11,400 against 1,050 for DAMGO — more than ten times as mu-selective (Schiller et al., Journal of Medicinal Chemistry, 1989, 32(3):698–703). Replacing the tyrosine with 2’,6’-dimethyltyrosine gave [Dmt1]DALDA, which showed high mu affinity and potency, systemic activity, and no cross-tolerance with systemic morphine (Riba et al., Current Medicinal Chemistry, 2002, 9(1):31–39; Schiller, AAPS Journal, 2005, 7(3):E560–E565). None of these reached the clinic as analgesics. The same aromatic-cationic tetrapeptide scaffold, however, was found by Szeto and Schiller to concentrate roughly a thousandfold in the inner mitochondrial membrane and scavenge reactive oxygen species (Zhao et al., Journal of Biological Chemistry, 2004, 279(33):34682–34690), a serendipitous observation that produced the SS peptides (Szeto & Birk, Clinical Pharmacology & Therapeutics, 2014, 96(6):672–683). The first of them, SS-31, is elamipretide, which the FDA approved on September 19, 2025, as Forzinity (NDA 215244, Stealth BioTherapeutics) for Barth syndrome. Elamipretide has no opioid activity; the relationship to dermorphin is one of chemical ancestry, not pharmacology. Newer dermorphin-derived constructs such as the dermorphin–ranatensin hybrid LENART01 remain at the rodent stage (Hochrainer et al., International Journal of Molecular Sciences, 2024, 25(7):4007).

The doping-control literature is the most active current research on the molecule itself. Intelligence from racetracks in 2011 suggested dermorphin was being used undetected, and positive findings at United States tracks followed from 2012. The first validated LC-MS/MS method, developed at the University of Pennsylvania’s School of Veterinary Medicine, reached detection limits of 10 pg/mL in plasma and 20 pg/mL in urine, distinguished dermorphin from its diastereomer, and was applied to official post-race samples (Guan et al., Analytical and Bioanalytical Chemistry, 2013, 405(14):4707–4717). Screens were quickly broadened to 17 dermorphin-family peptides in equine urine and plasma and human urine (Steel et al., Drug Testing and Analysis, 2014, 6(9):909–921), and to high-throughput human urine methods for the parent peptide and its dermorphin-(1-4) metabolite (Castro et al., Journal of Mass Spectrometry, 2020, 55(10):e4593). The pattern has since moved to the analogs: the Hong Kong Jockey Club laboratory identified [Dmt1]DALDA in a seized unlabeled vial and reported its first detection in horse urine (Choi et al., Drug Testing and Analysis, 2024, 16(3):268–276). The Association of Racing Commissioners International classifies dermorphin as a Class 1 substance in the most severe penalty category of its Uniform Classification Guidelines for Foreign Substances.

Common dosage forms

• Lyophilized research powder, supplied as the acetate or trifluoroacetate salt in milligram quantities for in vitro receptor binding, functional, and analytical work. This is the only format in which dermorphin is manufactured commercially.
• Analytical reference material and isotopically labeled internal standards, used by racing and anti-doping laboratories to calibrate the LC-MS/MS methods described above.
• Labeled receptor tools, including tritiated dermorphin and fluorophore conjugates such as [Cys(ATTO 488)8]dermorphin-NH2, used to visualize and quantify mu-opioid receptors in cells and tissue (Giakomidi et al., PLoS One, 2021, 16(4):e0250011).
• No administrable product exists. The solutions used in the 1980s Italian studies were prepared for those investigations and were never developed into a marketed presentation. There is no sterile injectable, no compounded preparation, and no oral, nasal, or topical form with any regulatory standing.

Key considerations

• The Research Market status reflects the absence of any approved dermorphin product in any jurisdiction, any pending application, and any registered clinical trial: an openFDA drug-label query returns no match and ClinicalTrials.gov lists no study as of November 3, 2026, and the compound is available only as a laboratory reagent.
• This is a full mu-opioid agonist many times more potent than morphine, and the animal record shows the complete opioid liability set. Respiratory depression with apnea, hypotension and bradycardia, catalepsy, tolerance within two days of continuous exposure, and naloxone-precipitated withdrawal have all been documented in rats. No controlled human safety dataset exists beyond a few dozen volunteers and one 1985 surgical series, so there is no modern human safety profile to cite, and the Sandrini study’s observation that naloxone reversed only about half of the spinal effect is an unresolved question rather than a reassurance.
• Its legal position for human use is unsettled rather than permissive. Dermorphin is a synthetic mu-opioid agonist with no approved medical use, and research-use labeling confers no exemption for human consumption. In sport it is unambiguously prohibited: racing regulators place it in their highest classification tier, and anti-doping laboratories have validated human urine methods for it and its metabolite.
• The evidence gap is nearly total at the human level. Everything of clinical character dates from 1983 to 1986, comes from two Italian groups, and was never replicated or registered. The optimized analogs did not reach approval as analgesics, and the scaffold’s only approved descendant, elamipretide, has no opioid activity.
• Naming confusions are common. “Dermorphine” with a terminal e is the same molecule in older European usage, and the 1985 intrathecal report uses that spelling. Hyp6-dermorphin, [Lys7]dermorphin, and [Lys7-NH2]dermorphin are natural or amidated family members with their own pharmacology, and the deltorphins from the same frogs are delta-selective peptides with a different receptor profile entirely. DALDA and [Dmt1]DALDA are synthetic tetrapeptides, not dermorphin, and dermorphin-(1-4) is the active N-terminal fragment and principal metabolite that doping laboratories target alongside the parent. The source animal is usually called the waxy monkey tree frog; “frog juice” is a racetrack colloquialism for synthetic dermorphin, not a skin extract.